Cell type-specific molecular mechanisms and implications of necroptosis in inflammatory respiratory diseases
- PMID: 37897080
- DOI: 10.1111/imr.13282
Cell type-specific molecular mechanisms and implications of necroptosis in inflammatory respiratory diseases
Abstract
Necroptosis is generally considered as an inflammatory cell death form. The core regulators of necroptotic signaling are receptor-interacting serine-threonine protein kinases 1 (RIPK1) and RIPK3, and the executioner, mixed lineage kinase domain-like pseudokinase (MLKL). Evidence demonstrates that necroptosis contributes profoundly to inflammatory respiratory diseases that are common public health problem. Necroptosis occurs in nearly all pulmonary cell types in the settings of inflammatory respiratory diseases. The influence of necroptosis on cells varies depending upon the type of cells, tissues, organs, etc., which is an important factor to consider. Thus, in this review, we briefly summarize the current state of knowledge regarding the biology of necroptosis, and focus on the key molecular mechanisms that define the necroptosis status of specific cell types in inflammatory respiratory diseases. We also discuss the clinical potential of small molecular inhibitors of necroptosis in treating inflammatory respiratory diseases, and describe the pathological processes that engage cross talk between necroptosis and other cell death pathways in the context of respiratory inflammation. The rapid advancement of single-cell technologies will help understand the key mechanisms underlying cell type-specific necroptosis that are critical to effectively treat pathogenic lung infections and inflammatory respiratory diseases.
Keywords: inflammation; inflammatory respiratory disease; mitochondrial dysregulation; necroptosis; oxidative stress; specific cell types.
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Xi Y, Chen L, Tang J, Yu B, Shen W, Niu X. Amplifying "eat me signal" by immunogenic cell death for potentiating cancer immunotherapy. Immunol Rev. 2023.
-
- Li S, Wang A, Wu Y, et al. Targeted therapy for non-small-cell lung cancer: new insights into regulated cell death combined with immunotherapy. Immunol Rev. 2023.
-
- Li L, Li T, Qu X, Sun G, Fu Q, Han G. Stress/cell death pathways, neuroinflammation, and neuropathic pain. Immunol Rev. 2023.
-
- Degterev A, Hitomi J, Germscheid M, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008;4(5):313-321.
-
- Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1(2):112-119.
Publication types
MeSH terms
Substances
Grants and funding
- 2023M731846/China Postdoctoral Science Foundation
- 2020CXGC011302/the Key Research and Development Program of Shandong Province (Major Science and Technology Innovation Project)
- 2022CXGC020506/the Key Research and Development Program of Shandong Province (Major Science and Technology Innovation Project)
- 82071021/the National Natural Science Foundation of China
- 82271146/the National Natural Science Foundation of China
LinkOut - more resources
Full Text Sources
Miscellaneous
